About

Developing Therapies from the Protective Human Immune Response

The MabVax antibody discovery technology identifies and recovers antibodies patients produce from vaccines administered against their cancers. We search and select for the very best antibody to be our development candidate. Our lead clinical development candidate, HuMab-5B1, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in over 90% of pancreatic cancer (PDAC) and in other diseases including small cell lung, colon and other GI cancers.

See the science behind HuMab-5B1

The Company's lead therapeutic program, MVT-1075, is a new HuMab-5B1 antibody based radioimmunotherapy (RIT) product, currently being evaluated in a Phase 1 clinical study for the treatment of pancreatic, colon and lung cancer. Patient enrollment and dosing in the initial cohort was completed in 2017 and interim data is expected in Q1 2018. MVT-1075 is being developed with in collaboration with Memorial Sloan Kettering Cancer Center and HonorHealth.

MVT-5873, the Company's therapeutic agent which utilizes the HuMab-5B1 antibody, is currently in Phase 1 development for patients with pancreatic cancer and other CA19-9 positive tumors. The Company completed its monotherapy Phase 1a trial and recently completed enrollment and initial patient dosing in an expanded cohort of the Phase 1 trial evaluating MVT-5873 in combination with a standard of care chemotherapy in newly diagnosed pancreatic cancer patients.

MVT-2163, the Company's immunoPET imaging diagnostic product which utilizes the HuMab-5B1 antibody coupled with a PET imaging agent, is in Phase 1 development for the diagnosis and treatment assessment of pancreatic cancer.

MVT-5873 and MVT-2163 are being developed with in collaboration with Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, HonorHealth and Imaging Endpoints, and have demonstrated early safety, specificity for the target and a potential efficacy signal.

View the Product Pipeline

For more information about the MabVax clinical programs, please visit www.clinicaltrials.com and reference the following identifier numbers that are associated with our lead clinical programs:

MVT-1075:  NCT03118349

MVT-5873:  NCT02672917

MVT-2163:  NCT02687230 
 

Identifying and Recovering the Right Antibodies

We study the protective immune response created by repeated vaccination of cancer patients. Our antibody discovery technology is able to identify and recover the antibodies patients have made from vaccines administered to patients against their cancers. We search for the very best antibodies made, from any patient receiving the vaccine and identify the optimal antibody that can then become an antibody development product candidate.

Proprietary approach to the discovery and development of novel fully human antibody therapy and diagnostic agents

Partnerships with Leading Research Centers

We are collaborating with several world-class oncology research and patient treatment organizations, including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, HonorHealth and Imaging Endpoints. We seek to leverage these valuable relationships with leading experts in the field to continue the development of our current products and explore follow-on opportunities.

View Partnerships

Contact Us

Contact us if you have questions about our company, antibody based therapeutics or any other questions or comments.

Contact Us